LEXICON PHARMACEUTICALS, INC. (LXRX)

Every figure this model derived for LXRX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 190,610,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 196,577,000 AssetsCurrent 2026-06-30
current liabilities 14,706,000 LiabilitiesCurrent 2026-06-30
equity 174,525,000 StockholdersEquity 2026-06-30
interest expense 6,048,000 InterestPaidNet 2026-06-30
ocf -64,988,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 41,469,000 Revenues 2026-06-30
sbc 12,693,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up LXRX on one particular measure came for.

RatioValue
cash operating margin-99.66
current ratio18.9
current ratio reported13.37
deferred revenue growth-100.0
dilution pct13.45
fcf margin-156.71
growth cv1.55
interest cover-9.01
operating margin-131.43
owner earnings margin-187.32
revenue growth-29.03
revenue growth per share-37.45
roic-121.8
rule of 40-160.46
sbc pct revenue30.61

What to be careful about

What this model itself distrusts about LXRX's figures. Written by the derivation as it ran, not added afterwards.